V-ATPase inhibition by archazolid increases the adhesion of MDA-MB-231 cells onto HUVECs and decreases their transendothelial migration. by Betty Luong (5738027)

Influenza virus infection decreases CLEC7A (Dectin1) mRNA and reduces phagocytosis of zymosan by AM. by Jieru Wang (179734)

“…<p>Panel A. Human AM were cultured and infected by PR/8 at a MOI of 0.5. …”

Table_1_Staple line lockstitch reinforcement decreases clinically relevant pancreatic fistula following distal pancreatectomy: Results of a propensity score matched retrospective a... by Feng Tian (121350)

“…The primary outcome was POPF rate.</p>Results<p>A total of 153 patients were enrolled in the study (89 lockstitch reinforcements, 64 non-reinforcements), of whom 128 patients (64 per group) were analyzed after propensity score matching (1:1). …”

<i>tra</i> regulates growth in a cell-autonomous, and a non cell-autonomous manner. by Elizabeth J. Rideout (651946)

“…(D) Expression of a <i>tra2-RNAi</i> transgene in the posterior compartment of the wing using <i>en-GAL4</i> caused a significant reduction in the ratio of posterior:anterior (p = 1.5 x 10⁻⁶; Student’s t-test). …”

Is species richness driving intra- and interspecific interactions and temporal activity overlap of a hantavirus host? An experimental test by André V. Rubio (4594702)

Subjects:

Treatment with wt- or S360A-(A)PC decreases infarct area. by Karin C. A. A. Wildhagen (599651)

50 WT 5′ and 3′ terminal nts of the S1 gene are sufficient to package a non-MRV gene into infectious virions. by Debarpan Dhar (724473)

Statins impact primary embryonic mouse neural stem cell survival, cell death, and fate through distinct mechanisms by Ross A. Carson (5184512)

“…To understand how statins could impact the developing brain, we studied effects of pravastatin and simvastatin on primary embryonic NSPC survival, proliferation, global transcription, and cell fate <i>in vitro</i>. We found that statins dose dependently decrease NSPC expansion by promoting cell death and autophagy of NSPCs progressing through the G1 phase of the cell cycle. …”

Differential expression analysis of nuclear transcripts after siAPOBEC3A depletion reveals induction of TP53 targets and decreases in cell cycle and cell growth regulator transcrip... by Mason A. McCool (11889842)

LD- and haplotype-based measures of epistasis identify a narrow time window of epistasis detectability. by Gabriele Pedruzzi (5753792)

<i>E. faecalis</i> metabolism decreases after exposure to bilirubin. by Christopher L. Nobles (437464)

Mice containing functional TSP-1 protein have decreased phagocytic capacity as compared to mice lacking functional TSP-1, and show increased survival in a non-surgical model of sepsis. by Sara McMaken (90003)

ExoY activity causes a decrease in microtubules in PMVECs. by Ron Balczon (453792)

The p.I126S mutation decreases FOXC1 DNA-binding. by Cristina Medina-Trillo (705087)

Efficacy of an herbal compound in decreasing steatosis and transaminase activities in non-alcoholic fatty liver disease: A randomized clinical trial by Seyyed Abbas Zojaji (5208589)

“…<div><p>Abstract Hepatoprotective effects of many herbal agents have been reported in animal studies and clinical trials. In this study, five hepatoprotective plants with potent antioxidant, anti-inflammatory, and hypolipidemic effects were chosen to prepare a polyherbal compound for managing NAFLD. …”

SLE T cells display more genes with increased rather than decreased expression. by Sean J. Bradley (823158)

“…<p><b>A)</b> Distribution of expression stratified at the 1.5-, 2-fold and q<0.05 CUFFDIFF2 significance levels. …”

Cell cycle-specific expression of Clb1 and Clb2 protein was also decreased in the <i>puf5</i>Δ mutant. by Megumi Sato (4116994)

Decreased capacity to infect is not correlated with a loss of metacyclic promastigotes. by Diana Moreira (186681)

Juvenile demyelination leads to a substantial decrease in potassium currents in PV interneurons of the PFC. by Sara Hijazi (21656615)

“…<p><b>A.</b> Representative traces of potassium currents evoked with 10 mV potential steps from −70mV to +60 mV in PFC PV interneurons from control (black) and cuprizone (red) mice. …”

Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

“…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”